In­cyte inks $750M deal for im­mune and neu­ro biotech Escient

In­cyte said it will pay $750 mil­lion to buy San Diego biotech Escient Phar­ma­ceu­ti­cals and its pipeline of ear­ly-stage drug can­di­dates.

The deal gives the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.